Cystic Fibrosis clinical trials at UCSF
5 in progress, 1 open to eligible people
Cystic fibrosis is a disease that affects the lungs and digestive system. At UCSF, we are doing a clinical trial to test a drug for treatment. We need healthy volunteers and people with cystic fibrosis to give sputum samples. There are three more trials going on, but they are not open for new participants.
CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment
open to eligible people ages 18-65
The investigators will collect samples of sputum from healthy volunteers and patients with cystic fibrosis for the purpose of: a) purifying airway mucins for plate-based binding studies and; b) assessment of the effects of carbohydrates on the rheologic properties of the sputum. This study has two hypotheses: 1. Lectins from Pseudomonas aeruginosa and Aspergillus fumigatus bind to airway mucins in a fucose-dependent manner, and this binding can be inhibited by fucosyl glycomimetic compounds. 2. Fucosyl glycomimetics will compete with Pseudomonas aeruginosa lectin (PA-IIL) and Aspergillus fumigatus lectin (AFL) and disrupt lectin-driven mucin cross-linking in CF sputum.
San Francisco, California
A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the efficacy and safety of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants who are heterozygous for F508del and a minimal function mutation (F/MF participants).
San Francisco, California and other locations
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
Sorry, accepting new patients by invitation only
The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.
San Francisco, California and other locations
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection
Sorry, not accepting new patients
The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.
San Francisco, California and other locations
Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
Sorry, accepting new patients by invitation only
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as retrospective standard of care patients
San Francisco, California and other locations
Our lead scientists for Cystic Fibrosis research studies include John Fahy.
Last updated: